Plasmodium falciparum: the effects of atovaquone resistance on respiration.
Atovaquone is an antimalarial agent that specifically inhibits the cytochrome bc(1) complex of the cytochrome pathway. High-level atovaquone resistance is associated with a point mutation in the cytochrome b gene. A pair of isogenic clinical isolates of Plasmodium falciparum derived from before and after the acquisition of atovaquone resistance was used to determine whether the change in the cytochrome b gene resulted in changes in respiration in response to atovaquone. Since P. falciparum appears to utilize a branched respiratory system comprising both the cytochrome and an alternative respiratory pathway, the proportion of each pathway utilized by the sensitive and resistant parasites was investigated. Atovaquone inhibited total parasite oxygen consumption by up to 66% in the sensitive isolate but only up to 28% in the resistant isolate. Both the atovaquone-sensitive and the atovaquone-resistant parasites were comparably sensitive to the alternative pathway inhibitor, salicylhydroxamic acid. Atovaquone appeared to partially inhibit the rate of oxygen consumed through the alternative pathway in only the atovaquone-sensitive isolate. Cross resistance was noted between atovaquone and a new antimalarial agent WR243251. However, the level of WR243251 resistance was very modest compared to the level of atovaquone resistance. WR243251 was shown to rapidly reduce the rate of parasite oxygen consumption by almost 80% in the atovaquone-sensitive isolate and by 57% in the atovaquone-resistant isolate. Drug interaction studies suggest that atovaquone and WR243251 may inhibit growth additively or with mild synergy. Together, these results suggest that while WR243251 may inhibit respiration, its target of action probably differs from that of atovaquone.
Suswam
E
E
Division of Geographic Medicine, University of Alabama at Birmingham, 1530 South 3rd Avenue, Birmingham, AL 35294-2170, U.S.A.
Kyle
D
D
Lang-Unnasch
N
N
D000166:Acridines / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D000981:Antiprotozoal Agents / Q000494:pharmacology; D053626:Atovaquone; D004347:Drug Interactions; D004351:Drug Resistance / Q000502:physiology; D006801:Humans; D009285:Naphthoquinones / Q000737:chemistry / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects / Q000502:physiology*; D012457:Salicylamides / Q000494:pharmacology
D000166:Acridines; D000962:Antimalarials; D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D012457:Salicylamides; C073155:WR 243251; C005703:salicylhydroxamic acid; D053626:Atovaquone